i-Inositol is a sugar alcohol involved in a series of biological processes such as insulin signal transduction and cytoskeleton transduction. i-Inositol is mainly present in glial cells and plays an osmotic role. i-Inositol can be used in research related to polycystic ovary syndrome, sperm function, and diabetes improvement[1-4].
In vitro, i-Inositol (100nM–10mM) was co-treated with PMA (1–100ng/ml), LPS (0.1–10μg/ml), IFN-γ (150unit/ml), or CsA (0.5–50nM) in RAW 264.7 mouse macrophages for 24 hours. i-Inositol restored taurine transport activity in a dose-dependent manner[5]. i-Inositol (0.02–0.10mg/ml) was used to treat DU-145 prostate cancer cells for 72 hours. i-Inositol significantly reduced cell viability[6].
In vivo, i-Inositol (360mg/kg/day) was orally administered daily to C57 BL/6J mice for 14 days. i-Inositol significantly reduced cadmium-induced serum urea nitrogen and creatinine levels, increased renal glutathione content and glutathione peroxidase activity, decreased tumor necrosis factor-α and inducible nitric oxide synthase expression, reduced monocyte chemoattractant protein-1, kidney injury molecule-1, and inositol oxygenase immunoreactivity, decreased the number of apoptotic cells, and protected kidney morphology[7]. i-Inositol (1.2mg/g/day) was intraperitoneally injected daily into female CD-1 Swiss mice for 15 days. i-Inositol significantly reduced white adipose tissue accumulation and improved insulin sensitivity in the mice[8].
References:
[1] Merviel P, James P, Bouée S, et al. Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies. Reprod Health. 2021 Jan 19;18(1):13.
[2] Bizzarri M, Monti N, Piombarolo A, et al. Myo-Inositol and D-Chiro-Inositol as Modulators of Ovary Steroidogenesis: A Narrative Review. Nutrients. 2023 Apr 13;15(8):1875.
[3] Benvenga S, Marini HR, Micali A, et al. Protective Effects of Myo-Inositol and Selenium on Cadmium-Induced Thyroid Toxicity in Mice. Nutrients. 2020 Apr 26;12(5):1222.
[4] Long L, Huang Q, Song T, Dai Z. Myo-inositol rescued insulin resistance and dyslipidemia in db/db mice. J Appl Biomed. 2024 Jun;22(2):74-80.
[5] Kim HW, Kim JH, An HS, et al. Myo-inositol restores the inflammation-induced down-regulation of taurine transport by the murine macrophage cell line, RAW 264.7. Life Sci. 2003 Sep 26;73(19):2477-89.
[6] Islam MJ, Muntaha S, Masum MM, et al. Proteomic Analysis of Anticancer Effect of Myo-inositol in Human Prostate Cancer (DU-145) Cell Line. Asian Pac J Cancer Prev. 2024 Dec 1;25(12):4447-4455.
[7] Pallio G, Micali A, Benvenga S, et al. Myo-inositol in the protection from cadmium-induced toxicity in mice kidney: An emerging nutraceutical challenge. Food Chem Toxicol. 2019 Oct;132:110675.
[8] Croze ML, Vella RE, Pillon NJ, et al. Chronic treatment with myo-inositol reduces white adipose tissue accretion and improves insulin sensitivity in female mice. J Nutr Biochem. 2013 Feb;24(2):457-66.
i-Inositol是一种参与胰岛素信号转导、细胞骨架转导等一系列生物过程的糖醇。i-Inositol主要存在于神经胶质细胞中起渗透作用。i-Inositol可用于多囊卵巢综合征、精子功能、糖尿病改善的相关研究[1-4]。
在体外，i-Inositol（100nM–10mM）与PMA（1–100ng/ml）、LPS（0.1–10μg/ml）、IFN-γ（150unit/ml）或CsA（0.5–50nM）共同处理RAW 264.7小鼠巨噬细胞24小时。i-Inositol以剂量依赖的方式恢复牛磺酸转运活性[5]。i-Inositol（0.02–0.10mg/ml）处理DU-145前列腺癌细胞72小时。i-Inositol显著降低细胞活力[6]。
在体内，i-Inositol（360mg/kg/day）每日口服，用于处理C57 BL/6J小鼠14天。i-Inositol显著降低了镉诱导的血清尿素氮和肌酐水平，增加了肾脏谷胱甘肽含量和谷胱甘肽过氧化物酶活性，降低了肿瘤坏死因子-α和诱导型一氧化氮合酶表达，减少了单核细胞趋化蛋白-1、肾损伤分子-1和肌醇加氧酶免疫反应性，减少了凋亡细胞数量，并保护了肾脏形态[7]。i-Inositol（1.2mg/g/day）每日腹腔注射，用于处理雌性CD-1 Swiss小鼠15天。i-Inositol显著减少了小鼠的白色脂肪组织积累并改善了胰岛素敏感性[8]。